We explore your current symptoms, baseline energy and recovery capacity, digestive function, hormonal patterns, sleep quality, and how past treatments have responded in your individual biology
You can read more about the brands standards here
March 3rd, 2026: Federal Judge Appoints Leadership for GLP1 Vision Loss Lawsuits Multiple lawsuits alleging vision loss from GLP1 drugs, including Ozempic, Wegovy, and Mounjaro have been consolidated into a multidistrict litigation in the Eastern District of Pennsylvania, the same court responsible for handling GLP-1 lawsuits involving gastrointestinal injuries
TRX2 treatments increase the anagen to telogen hair ratio The higher the hair loss rate is, the lower is the ratio of anagen to telogen hairs (A/T ratio)
GLOW is a research peptide blend combining BPC-157, TB-500, and GHK-Cu in a single lyophilized vial
doi: 10.1093/jn/125.6.1401 3